Multi-omics analysis has characterized the ceramide/sphingomyelin pathway as a therapeutic target for Alzheimer’s disease, and mouse experiments have depicted that long-term exposure to fingolimod alleviates synaptic plasticity and cognitive impairment in mice, and modulators of S1P metabolism have become possible candidates for Alzheimer’s disease treatment (134). This evidence concerns the gene MBTPS1 and Alzheimer disease.